Claudio Laudani/X
Aug 8, 2025, 15:28
Claudio Laudani: New Insights on P2Y12 Monotherapy in Antiplatelet Therapy
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on X:
”The landscape of antiplatelets has changed in the last decade, shifting from the initial focus on long-term DAPT to P2Y12 inhibitor monotherapy. In this review, we summarize the pharmacology and clinical evidence on antiplatelet montherapy.”
Read the full article here.
Title: Antiplatelet Monotherapies for Long-Term Secondary Prevention Following Percutaneous Coronary Intervention
Authors: Claudio Laudani, Daniele Giacoppo, Antonio Greco, Luis Ortega-Paz, Georges El Khoury, Davide Capodanno, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Nov 8, 2025, 05:31Phenotyping of Human Platelets by Daisie Yates
-
Nov 8, 2025, 04:35Inaugural Women In Hematology US Focus Meeting 2025 Officially Commenced
-
Nov 7, 2025, 06:59Stephen Cornelissen is Celebrating an Extraordinary Milestone at Australian Red Cross Lifeblood
-
Nov 7, 2025, 06:56Reza Shojaei on Leadership in the Blood and Plasma Sector
-
Nov 7, 2025, 06:52Rachel Margolis-Goodman Announces Groundbreaking Expension of Versiti Blood Research Institute
-
Nov 7, 2025, 06:46What’s New in HIT from THANZ Webinar Series
-
Nov 7, 2025, 03:30Abdallah Othman About Cardiac Vasculature
-
Nov 7, 2025, 03:29Aabha Divya: Thrilled to Share Our Latest Publication in Annals of Thoracic Surgery Short Reports!
-
Nov 7, 2025, 03:28Shantel Holcomb: Boston Scientific is Investing in Innovative Solutions to Improve Outcomes for Patients With CAD